Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics, Inc.'s share was trading at $38.26 as of June 15th. RAPP’s trailing P/E was 23.78 according to Yahoo Finance.
[caption id="attachment_575379" align="aligncenter" width="750"]Rapport Therapeutics (RAPP) is a Boston-based clinical-stage biotechnology company developing precision therapies for serious neurological and psychiatric disorders,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.